Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Navaprin Vet is a veterinary antiparasitic medication containing eprinomectin, a semi-synthetic macrocyclic lactone of the avermectin family. Developed by Navana Pharmaceuticals, it is formulated as a topical pour-on solution for the treatment and control of internal and external parasites in livestock, such as beef and dairy cattle, as well as domestic animals like cats. Eprinomectin acts by selectively binding with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to hyperpolarization, paralysis, and death of the parasites. It is highly effective against gastrointestinal roundworms, lungworms, grubs, sucking and biting lice, mites, and horn flies, offering a wide safety margin and zero withdrawal periods for meat and milk.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eprinomectin.